A Phase 4 interventional study of 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 5 sites in India. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-26.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 33rd largest by enrollment, is one of 3 that started in 2022, is one of 11 in phase 4, and was the 40th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 3 started in 2022.
This study's enrollment of 200 is below the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 49th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2022, is one of 7 in phase 4, and was the 57th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pneumococcal conjugate vaccine (13vPnC)
Biological: 13-valent pneumococcal conjugate vaccine
One dose of 13vPnC (0.5mL) will be administered intramuscularly.
Percentage of Participants With Prompted Local Reactions Within 7 Days After Vaccination
From Day 1 through Day 7 following vaccination, where Day 1 is the day of vaccination, local reactions including redness, swelling, and pain at the injection site were assessed and recorded.
Time frame: Within 7 Days After Vaccination
Percentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination
From Day 1 through Day 7 following vaccination, where Day 1 is the day of vaccination, systemic events including fever, headache, fatigue, muscle pain, and joint pain were assessed and recorded. Fever was defined as temperature ≥38.0 °C.
Time frame: Within 7 Days After Vaccination
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local reactions (redness, swelling, and pain at the injection site) and systemic events (fever, headache, fatigue, muscle pain, and joint pain) were not collected as AEs.
Time frame: Within 1 Month After Vaccination
Percentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination
An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.
Time frame: Within 1 Month After Vaccination
This study was conducted in India. Participants took part in the study for approximately 1 month.
| Milestone | 13vPnC |
|---|---|
| Started | 200 |
| Completed | 200 |
| Not completed | 0 |
| Milestone | 13vPnC |
|---|---|
| Started | 200 |
| Completed | 200 |
| Not completed | 0 |
From Day 1 through Day 7 following vaccination, where Day 1 is the day of vaccination, local reactions including redness, swelling, and pain at the injection site were assessed and recorded.
| Percentage | 13vPnC |
|---|---|
| Redness | 1.5 (0.3 to 4.3) |
| Swelling | 6.5 (3.5 to 10.9) |
| Pain at Injection Site | 63.0 (55.9 to 69.7) |
From Day 1 through Day 7 following vaccination, where Day 1 is the day of vaccination, systemic events including fever, headache, fatigue, muscle pain, and joint pain were assessed and recorded. Fever was defined as temperature ≥38.0 °C.
| Percentage | 13vPnC |
|---|---|
| Fever | 3.0 (1.1 to 6.4) |
| Fatigue | 25.0 (19.2 to 31.6) |
| Headache | 23.0 (17.4 to 29.5) |
| Joint Pain | 7.5 (4.3 to 12.1) |
| Muscle Pain | 32.0 (25.6 to 38.9) |
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local reactions (redness, swelling, and pain at the injection site) and systemic events (fever, headache, fatigue, muscle pain, and joint pain) were not collected as AEs.
| Percentage | 13vPnC |
|---|---|
| Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination | 0.5 (0.0 to 2.8) |
An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.
| Percentage | 13vPnC |
|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination | 0 (0 to 1.8) |
Collected over Within 1 month after vaccination.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC | 0/200 (0%) | 0/200 (0%) | 1/200 (0.5%) |
| Event | 13vPnC |
|---|---|
| VaricellaInfections and infestations | 1/200 |
All participants who received any study intervention and had safety data assessed after vaccination.
| Age, Continuous(Years) | 13vPnC |
|---|---|
| Mean | 31.4 ± 7.98 |
| Age, Continuous(Years) | 13vPnC |
|---|---|
| Median | 29.0 (18 to 49) |
| Sex: Female, Male(Participants) | 13vPnC |
|---|---|
| Female | 92 |
| Male | 108 |
| Race/Ethnicity, Customized(Participants) | 13vPnC |
|---|---|
| Race_Asian | 200 |
| Ethnicity_Non-Hispanic/Non-Latino | 200 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2022 to primary completion in Nov 2022, 1 month.
Results were first posted in Apr 2024, 1 year 4 months after primary completion.
Of 21 phase 4 interventional studies under Pneumococcal Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine